Search for: "Lisa Ouellette" Results 121 - 140 of 162
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Are patents the cause of—or solution to—COVID-19 vaccine innovation problems? (No!)
4 Mar 2021, 10:50 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers encourage COVID-19 vaccine trials for children?
18 Dec 2020, 6:37 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsThe past two weeks have been full [read post]
Written Description - http://writtendescription.blogspot.com/
How is the NIH seeking to encourage investment in diagnostic testing for COVID-19?
13 Aug 2020, 8:09 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about [read post]
Written Description - http://writtendescription.blogspot.com/
Guest Post: Spurring and Clearing the Path for Open COVID Innovation Through Contextual Patent Disclosure
20 May 2020, 1:58 pm by Jason Rantanen
Chien is a Professor at Santa Clara University School of Law. [1] Professor Lisa Ouellette’s Written [read post]
Patently-O - https://patentlyo.com
What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?
30 Nov 2020, 7:24 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWhen President-elect Joe Biden is inaugurated in [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine manufacturers aiming to encourage trust in the FDA’s approval process?
2 Oct 2020, 7:10 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn recent weeks, a number of articles have reported [read post]
Written Description - http://writtendescription.blogspot.com/
Multi-Agency Funding for COVID-19 Vaccine Development
19 Aug 2020, 10:58 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers use “pull” mechanisms to improve COVID-19 innovation incentives?
30 Jul 2020, 3:39 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers incentivize and regulate convalescent serum therapy for COVID-19?
22 Jul 2020, 12:12 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon [read post]
Written Description - http://writtendescription.blogspot.com/
Law Prof Twitter Census Version 3.0 -- Call for Entries
6 Jan 2015, 6:46 pm by Bridget Crawford
Louis University Tom McDonnell McDonnellTomLaw Pace Lisa McElroy ProfLisaMcElroy Drexel William McGeveran [read post]
The Faculty Lounge - https://www.thefacultylounge.org/
Why do differences in clinical trial design make it hard to compare COVID-19 vaccines?
30 Jun 2021, 10:31 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine developers and regulators responding to variants?
25 Mar 2021, 1:24 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
12 Jan 2021, 9:04 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How will the FDA’s new COVID-19 vaccine guidance affect development efforts?
10 Jul 2020, 8:59 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development [read post]
Written Description - http://writtendescription.blogspot.com/
Sapna Kumar: The Fate Of "Innovation Nationalism" In The Age of Trump
9 Mar 2018, 12:54 pm by Camilla Alexandra Hrdy
To give one example, in their recent article, Bayh-Dole Without Borders, Lisa Larrimore Ouellette [read post]
Written Description - http://writtendescription.blogspot.com/
What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies?
21 Jan 2022, 8:35 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe FDA has now authorized three vaccines and several [read post]
Written Description - http://writtendescription.blogspot.com/
How can health regulators maintain public trust when facing scientific uncertainty?
24 Jun 2020, 5:36 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part II: Allocating Access
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives [read post]
Written Description - http://writtendescription.blogspot.com/
Regulatory Responses to N95 Respirator Shortages
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted [read post]
Written Description - http://writtendescription.blogspot.com/
How can innovation and regulatory policy accomplish robust COVID-19 testing?
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that [read post]
Written Description - http://writtendescription.blogspot.com/